|
||||
2024-05-07 07:30:00 CEST 2024-05-07 07:30:00 CEST REGULATED INFORMATION Orion - Changes board/management/auditorsOrion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025ORION CORPORATION Olli Huotari, Senior Vice President responsible for Corporate Functions organization (including, i.a., Communications, Compliance, Corporate Responsibility, Intellectual Property Rights, Legal Affairs and Public Affairs) of the Orion Group and Secretary to the Board of Directors of Orion Corporation, and a member of the Executive Management Board of the Orion Group has informed the company of his decision to leave Orion. Orion will start a recruiting process of the successor to Olli Huotari. In order to secure a proper transition of responsibilities to his successor, Orion and Huotari have agreed that Huotari will continue in his current positions at Orion (including the membership of the Executive Management Board of the Orion Group) until 31 May 2025, after which he will leave the company. Olli Huotari has held group-level leadership positions at Orion since 2002. President and CEO Liisa Hurme says: “I want to warmly thank Olli for his great work for Orion. It is of course a pity when such a proficient and experienced leader wants to leave. However, as much as we would like to keep him with the company, we must respect his decision. We are pleased that Olli has agreed to continue working at Orion for a sufficient period in order to ensure a smooth transition of responsibilities and introduction of his successor. This also reflects Olli as a person − he always wants to make sure that the company’s interests are taken care of.” Olli Huotari says: Orion Corporation
Contact person for the media: Publisher: Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. |
||||
|